Trial Profile
Lamivudine for Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications Glomerulonephritis; Hepatitis B; Hepatitis D; Periarteritis nodosa
- Focus Adverse reactions; Therapeutic Use
- 25 Jul 2016 New trial record
- 03 Jul 2016 Results published in the Alimentary Pharmacology and Therapeutics